Tandem Diabetes Q3 sales rise on international growth; reaffirms 2026 outlook
TNDM•Tandem’s Q3 revenue rose 14% year over year to $283.7 million, while gross margin reached 57% and operating loss narrowed to $2.4 million. The company reaffirmed 2026 sales guidance of $1.065 billion to $1.085 billion.
1. Quarterly results
Tandem Diabetes reported Q3 revenue of $283.7 million, up 14% year over year. Gross margin improved to 57%, operating loss narrowed to $2.4 million, and net loss was $7.10 million.
2. 2026 outlook
The company reaffirmed its 2026 sales guidance of $1.065 billion to $1.085 billion, including U.S. sales of $730 million to $745 million and international sales of $335 million to $340 million. It projects 2026 gross margin of 56% to 57% of sales.
3. Growth drivers
Tandem said its expanded pay-as-you-go pharmacy channel accounted for 15% of U.S. sales. It expanded t:slim X2 compatibility with the Abbott FreeStyle Libre 3 Plus Sensor to 11 international markets and launched Tandem Mobi in 12 countries.
